In their study, Bug et al. showed how the levels of mutant p53 are increased in cancer cells after exposure to doxorubicin and daunorubicin [68], mainly through activation of DNA damage-responsive kinase ataxia telangiectasia mutated [80]. Here, TP53 is linked to cancer.